Jump Financial, LLC Geron Corp Transaction History

Jump Financial, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$4.17 - $4.99 $636,759 - $761,973	-152,700 Closed	0 $0
Q2 2024 Aug 14, 2024	BUY	$3.1 - $5.09 $473,370 - $777,243	152,700 New	152,700 $647,000
Q3 2023 Oct 21, 2024	BUY	$2.11 - $3.28 $1.58 Million - $2.46 Million	750,001 Added 922.43%	831,308 $1.76 Million
Q3 2023 Nov 07, 2023	BUY	$2.11 - $3.28 $1.58 Million - $2.46 Million	750,001 Added 922.43%	831,308 $1.76 Million
Q2 2023 Oct 21, 2024	BUY	$1.97 - $3.69 $18,925 - $35,449	9,607 Added 13.4%	81,307 $260,000
Q2 2023 Aug 07, 2023	BUY	$1.97 - $3.69 $18,925 - $35,449	9,607 Added 13.4%	81,307 $260,000
Q1 2023 Oct 21, 2024	SELL	$2.14 - $3.4 $173,340 - $275,400	-81,000 Reduced 53.05%	71,700 $155,000
Q1 2023 May 03, 2023	BUY	$2.14 - $3.4 $153,438 - $243,780	71,700 New	71,700 $155,000
Q4 2021 Feb 10, 2022	SELL	$1.22 - $1.72 $32,452 - $45,752	-26,600 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$1.2 - $1.5 $31,920 - $39,900	26,600 New	26,600 $36,000

278

491M

1.87M

690K

Ticker GERN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 377,819,008
Market Cap $1.14B
Description
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hemat...

Get notified when there are updates to the investment portfolio of Jump Financial, LLC, based on Form 13F filings with the SEC.

Stay updated on Jump Financial, LLC with notifications on news.